The Endocannabinoid System in the Regulation of Cardiometabolic Risk Factors

American Journal of Cardiology

Volumn 100, Issue 12 SUPPL. 1, 2007, Pages S7-

  Bellocchio, Luigi ^a   Vicennati, Valentina ^a   Cervino, Cristina ^a   Pasquali, Renato ^a   Pagotto, Uberto ^a  

^a Applied Biomedical Research Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABIS; CHOLECYSTOKININ; ENDOCANNABINOID; GHRELIN; GLUCOCORTICOID; INSULIN; LEPTIN; MALONYL COENZYME A; RIMONABANT;

ADIPOSE TISSUE; ARTICLE; CALORIC INTAKE; CARDIOMETABOLIC RISK FACTOR; CARDIOVASCULAR RISK; ENERGY; ENERGY METABOLISM; FOOD; FOOD INTAKE; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; HYPOTHESIS; LIMBIC SYSTEM; LIVER; METABOLISM; MODULATION; NONHUMAN; OBESITY; ORGAN; PANCREAS ISLET; PRIORITY JOURNAL; REGULATORY MECHANISM; SKELETAL MUSCLE;

EID: 37249050950     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.10.009     Document Type: Article

References (103)

1. Broberger C. Brain regulation of food intake and appetite: molecules and networks. J Intern Med 258 (2005) 301-327
2. Abizaid A., Gao Q., and Horvath T.L. Thoughts for food: brain mechanisms and peripheral energy balance. Neuron 51 (2006) 691-702
3. King B.M. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 87 (2006) 221-244
4. Lebrun B., Bariohay B., Moyse E., and Jean A. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. Auton Neurosci 126 (2006) 30-38
5. Xu B., Goulding E.H., Zang K., Cepoi D., Cone R.D., Jones K.R., Tecott L.H., and Reichardt L.F. Brain-derived neurotrphic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6 (2003) 736-742
6. Fadel J., and Deutch A.Y. Anatomical substrates of orexin-dopamine interaction: lateral hypothalamic projections to the ventral tegmental area. Neuroscience 111 (2002) 379-387
7. Appleyard S.M., Bailey T.W., Doyle M.W., Jin Y.H., Smart J.L., Low M.J., and Andresen M.C. Proopiomelanocortin neurons in nucleus tractus solitarius are activated by visceral afferents: regulation by cholecystokinin and opioids. J Neurosci 25 (2005) 3578-3585
8. Spanagel R., and Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 22 (1999) 521-527
9. Ahima R.S., Prabakaran D., Mantzoros C., Qu D., Lowell B., Maratos-Flier E., and Flier J.S. Role of leptin in the neuroendocrine response to fasting. Nature 382 (1996) 250-252
10. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., Fei H., Kim S., Lallone R., Ranganathan S., Kern P.A., and Friedman J.M. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1 (1995) 1155-1161
11. Komori T., Morikawa Y., Nanjo K., and Semba E. Induction of brain-derived neurotrophic factor by leptin in the ventromedial hypothalamus. Neuroscience 139 (2006) 1107-1115
12. Woods S.C., Lotter E.C., McKay L.D., and Porte Jr. D. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282 (1979) 503-505
13. Obici S., Feng Z., Karkanias G., Baskin D.G., and Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 5 (2002) 566-572
14. Pocai A., Obici S., Schwartz G.J., and Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab 1 (2005) 53-61
15. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
16. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., and Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
17. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., and Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 (2001) 1714-1719
18. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., Kangawa K., and Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 (2002) 1120-1128
19. Wang L., Saint-Pierre D.H., and Tache Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y-synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 325 (2002) 47-51
20. Cohn F., Schago E., and Joseph D. Effect of food administration on weight gains and body composition of normal and adrenalectomized rats. Am J Physiol 180 (1955) 503-507
21. Green P.K., Wilkinson C.W., and Woods S.C. Intraventricular corticosterone increases the rate of body weight gain in underweight adrenalectomized rats. Endocrinology 130 (1992) 269-275
22. Chavez M., Seeley R.J., Green P.K., Wilkinson C.W., Schwartz M.W., and Woods S.C. Adrenalectomy increases sensitivity to central insulin. Physiol Behav 62 (1997) 631-634
23. Zakrzewska K.E., Cusin I., Sainsbury A., Rohner-Jeanrenaud F., and Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 46 (1997) 717-719
24. Laugero K.D., Bell M.E., Bhatnagar S., Soriano L., and Dallman M.F. Sucrose ingestion normalizes central expression of corticotropin-releasing factor mRNA and energy balance in adrenalectomized rats: a glucocorticoid-metabolic-brain axis?. Endocrinology 142 (2001) 2796-2804
25. Folmes C.D., and Lopaschuk G.D. Role of malonyl-CoA in heart disease and the hypothalamic control of obesity. Cardiovasc Res 73 (2007) 278-287
26. López M., Tovar S., Vásquez M.J., Nogueiras R., and Señarís Dieguez C. Sensing the fat: fatty acid metabolism in the hypothalamus and the melanocortin system. Peptides 26 (2005) 1753-1758
27. Kim E.K., Miller I., Aja S., Landree L.E., Pinn M., McFadden J., Kuhajda F.P., Moran T.H., and Ronnett G.F. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 279 (2004) 19970-19976
28. Kim E.K., Miller I., Landree L.E., Borisy-Rudin F.F., Brown P., Tihan T., Townsend C.A., Witters L.A., Moran T.H., Kuhajda F.P., and Ronnett G.V. Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment. Am J Physiol Endocrinol Metab 283 (2002) 867-879
29. Minokoshi Y., Alquier T., Furukawa N., Kim Y.B., Lee A., Xue B., Mu J., Foufelle F., Ferré P., Birnbaum M.J., Stuck B.J., and Kahn B.B. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 (2004) 569-574
30. Gibbs J., Young R.C., and Smith G.P. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84 (1973) 488-495
31. Schwartz G.J., McHugh P.R., and Moran T.H. Integration of vagal afferent responses to gastric loads and cholecystokinin in rats. Am J Physiol Regul Integr Comp Physiol 261 (1991) R64-R69
32. Schwartz G.J., McHugh P.R., and Moran T.H. Gastric loads and cholecystokinin synergistically stimulate rat gastric vagal afferents. Am J Physiol Regul Integr Comp Physiol 265 (1993) R872-R876
33. Peters H., and Nahas G.G. A brief history of four millennia (B.C. 2000-A.D. 1974). In: Nahas G.G., Sutin K., Harvey D., and Agurell S. (Eds). Marihuana and Medicine (1999), Humana Press, Totowa, NJ 3-7
34. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86 (1964) 1646-1647
35. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., and Pagotto U. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27 (2003) 289-301
36. Abel E.L. Cannabis: effects on hunger and thirst. Behav Biol 15 (1975) 255-281
37. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
38. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
39. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
40. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
41. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4 (2003) 873-884
42. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990) 1932-1936
43. Horvath T.L. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 122 (2003) 323-326
44. 9-THC and anandamide. Physiol Behav 76 (2002) 241-250
45. Kirkham T.C., Williams C.M., Fezza F., and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136 (2002) 550-557
46. 1) receptors. Psychopharmacology 132 (1997) 104-106
47. Freedland C.S., Poston J.S., and Porrino L.J. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 67 (2000) 265-270
48. 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9 (1998) 179-181
49. Verty A.N., McGregor I.S., and Mallet P.E. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 354 (2004) 217-220
50. 9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology (Berl) 165 (2003) 370-377
51. Gardner E.L., and Vorel S.R. Cannabinoid transmission and reward-related events. Neurobiol Dis 5 (1998) 502-533
52. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., and Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256 (1999) 377-380
53. Hermann H., Marsicano G., and Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109 (2002) 451-460
54. 9-tetrahydrocannabinol. Brain Res 1020 (2004) 188-195
55. 1 receptors. J Neurosci 24 (2004) 53-62
56. Corchero J., Manzanares J., and Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 16 (2004) 159-172
57. Bakshi V.P., and Kelley A.E. Feeding induced by opioid stimulation of the ventral striatum: role of opiate receptor subtypes. J Pharmacol Exp Ther 265 (1993) 1253-1260
58. Kirkham T.C., and Williams C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 153 (2001) 267-270
59. Rowland N.E., Mukherjee M., and Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159 (2001) 111-116
60. Hanus L., Avraham Y., Ben-Shushan D., Zolotarev O., Berry E.M., and Mechoulam R. Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in the mouse brain. Brain Res 983 (2003) 144-151
61. Jamshidi N., and Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134 (2001) 1151-1154
62. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
63. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
64. Jo J.H., Chen Y.J., Chua Jr. S.C., Talmage D.A., and Role L.W. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 48 (2005) 1055-1066
65. 1 antagonist, SR141716. J Biol Chem 278 (2003) 23731-23737
66. Gamber K.M., Macartur H., and Westfall T.C. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 143 (2005) 520-523
67. 1 cannabinoid and melanocortin MC4 receptors in regulating food intake. Endocrinology 145 (2004) 3224-3231
68. Osei-Hyiaman D., Depetrillo M., Harvey-White J., Bannon A.W., Cravatt B.F., Kuhar M.J., Mackie K., Palkovits M., and Kunos G. Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81 (2005) 273-282
69. Hermann H., and Lutz B. Coexpression of cannabinoid receptor type 1 with the corticotropin-releasing hormone receptor type 1 in distinct region of mouse adult forebrain. Neurosci Lett 75 (2005) 13-18
70. Di S., Malcher-Lopes R., Marcheselli V.L., Bazan N.G., and Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 375 (2003) 13-18
71. Malcher-Lopes R., Di S., Marcheselli V.S., Weng F.J., Stuart C.T., Bazan N.G., and Tasker J.G. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 26 (2006) 6643-6650
72. Tucci S.A., Rogers E.K., Korbonits M., and Kirlham T.C. The cannabinoid receptor antagonist SR141716 blocks the orexigenic effect of intrahypothalamic ghrelin. Br J Pharmacol 143 (2004) 520-523
73. Cani P.D., Montoya M.L., Neyrinck A.M., Delzenne N.M., and Lambert D.M. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoids compound, SR141716 (rimonabant) and oleoylethanolamide. Br J Nutr 92 (2004) 757-761
74. Bayatti N., Hermann H., Lutz B., and Bhal C. Corticotropin-releasing hormone-mediated induction of intracellular signaling pathways and brain-derived neurotrophic factor expression is inhibited by the activation of the endocannabinoid system. Endocrinology 146 (2005) 1205-1213
75. 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
76. Kola B., Hubina E., Tucci S.A., Kirkham T.C., Garcia E.A., Mitchell S.E., Williams L.M., Hawley S.A., Hardie D.G., Grossman A.B., and Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic effects via AMP-activated protein kinase. J Biol Chem 280 (2005) 25196-25202
77. 1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22 (2002) 9612-9617
78. 1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24 (2004) 2708-2715
79. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
80. 1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increase markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 9 (2006) 471-478
81. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., and Casellas P. Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517 (2005) 174-181
82. Kadowaki T., and Yamamuchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 493-451
83. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 406-430
84. Perwitz N., Fasshauer M., and Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 38 (2006) 356-358
85. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino P., Pasquali R., Maj M., Pagotto U., and Di Marzo V. Regulation, function and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91 (2006) 3171-3180
86. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A.M., and Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
87. Spoto B., Fezza F., Parlongo G., Battista N., Sgro' E., Gasperi V., Zoccali C., and Maccarrone M. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 88 (2006) 1889-1897
88. Gonthier M.P., Hoareau L., Festy F., Matias I., Valenti M., Bes-Houtmann S., Rouch C., Robert-Da Silva C., Chesne S., Lefebvre d'Hellencourt C., et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity 15 (2007) 837-845
89. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100
90. Cavuoto P., McAincha A.J., Hatzinikolas G., Cameron-Smith D., and Wittert G.A. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267 (2007) 63-69
91. 2+ signals and insulin secretion in pancreatic beta-cells. Cell Calcium 39 (2006) 155-162
92. 1 receptors induces glucose intolerance in rats. Eur J Pharmacol 531 (2006) 282-284
93. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., and Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63 (1998) 113-117
94. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284 (2003) R345-R353
95. 1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 62 (2003) 125-132
96. 1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19 (2005) 1567-1569
97. Shearman L.P., Zhou D., Rosko K.M., Camacho R.E., Stribling D., MacIntyre D., and Strack A.M. Multiple day CB1R inverse agonist effects on hypothalamic gene expression and energy balance in diet-induced obese mice. Presented at the 34th Annual Meeting of the Society for Neuroscience; October 23-27; San Diego, California. Abstract p 76.4 (2004)
98. ob mice. Int J Obes Relat Metab Disord 9 (2005) 183-187
99. Poirier B., Bidouard J.P., Cadrouvele C., Marniquet X., Staels B., O'Connor S.E., Janiak P., and Herbert J.M. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7 (2005) 65-72
100. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (2005) 585-589
101. Blüher M., Engeli S., Klöting N., Berndt J., Fasshauer M., Bátkai S., Pacher P., Schön M.R., Jordan J., and Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55 (2006) 3053-3060
102. Lofgren P., Sjolin E., Wahlen K., and Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 92 (2007) 1555-1559
103. Côté M., Matias I., Lemieux I., Petrosino S., Almèras1 N., Després J.-P., and Di Marzo V. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 31 (2007) 692-699